erapy, it the majority of subjects responded to treatment. Specifically, 45.5 percent of participants responded with a greater than 50 percent reduction in prostate specific antigen (PSA) from their post-holiday baseline; of those, 45.5 percent had stable PSAs for at least 12 weeks; and 9.1 percent developed disease progression. Prostate-specific antigen is a protein produced by the cells of the prostate gland and is present in small quantities in the serum of healthy men, and it often elevates when prostate cancer is present. Most men have less than 4 nanograms. Anything higher can indicate prostate cancer.
The next step, said Beer, is to study the addition of immunotherapy, treating the cancer by working with the immune system, during the chemotherapy holidays.
Because we know holidays are a good thing, we want to find ways to make them even longer, Beer said.
OHSU and Beer have significant financial interest in Novacea, Inc., a company that has a commercial interest in the results of this research and technology. This potential conflict was reviewed and a management plan approved by the OHSU Conflict of Interest in Research Committee and the Integrity Program Oversight Council was implemented.
'/>"/>
Page: 1 2 Related medicine news :1.
Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men2.
Survival differences by race most apparent in advanced stages of breast cancer3.
MRI finds breast cancer before it becomes dangerous4.
Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer5.
Pathway links inflammation, angiogenesis and breast cancer6.
Radiologists encouraged to look beyond cancer for clinically unseen diseases7.
Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death8.
Immune deficiency linked to a type of eye cancer9.
Drop in breast cancer incidence linked to hormone use, not mammograms10.
Breast cancer prevention practices vary across Canada11.
First biomarker discovered that predicts prostate cancer outcome